Yeah and the important thing is that by the time that happens, a fair chunk of people will have full protection too, it isn't going to be stuck around the numbers it is now.
Agree with you though, there's more than one way to skin a cat.
I've been persistent with the Pfizer one that I don't think we should mess with it or at the least reduce the spacing to 6 weeks like Denmark and France.
That being said, until/unless we see actual evidence that it's not working at 12 weeks with Pfizer then the plan will be justified.
Also, this might be a daft question, but could Pfizer not, y'know, run more tests like AZ are doing, and over a longer spacing rather than 3 weeks? Is that not possible - or are they already doing it?
Very true mate, priority groups in the UK - health care workers i know many who have two does already.
Its going to be interesting to see how it all plays out, UK strategy is to minimize death and hospitalizations by giving everyone the best protection, Vs Eu strategy of double dose for full protection again to reduce serious cases, with the added benefit of reaching herd immunity quicker.
All that said the research from AZ yesterday will likely see both strategies become closer together as if both regions will be working a 12 week programme i assume with AZ anyway, once Az arrives in Europe i expect you will see EU numbers rise significantly quickly on that bases as the nature of the vaccine means you have a longer time to procure the second in comparison to Pfizer or Moderna.
I haven't seen any mate, im not sure there are many countries doing the 12 weeks with MRNA and the Uk would be the biggest, so i dont think research was planned. Someone somewhere will be keeping an eye on it but im not sure that research was planned. id like to the logic from the UKs CMO, they have obviously done some. The big worry i think for the UK will be the vacuum of variants the strategy might empower, but we dont yet.
Personally i think Pfizer have a strategy, their vaccine isnt sustainable and they know this, their pitch was always getting to market first, early and at a high price, they know more functional vaccines without a cold chain are coming behind and i suspect the have already moved on the gen 2, the next big money is going to be made treating new variants and having a more functional vaccine, so im not sure they will be doing much with what they already have in place..